StemCell Therapy

APRIL 07, 2020 --Endocrinologists have underlined the importance that physicians consider "a stress dose" of glucocorticoids in the event of severe COVID-19 infection in endocrine, and other, patients on long-term steroids.

People taking corticosteroids on a routine basis for a variety of underlying inflammatory conditions, such as asthma, allergies, and arthritis, are at elevated risk of being infected with, and adversely affected by, COVID-19.

This also applies to a rarer group of patients with adrenal insufficiency and uncontrolled Cushing syndrome, as well as secondary adrenal insufficiency occurring in hypopituitarism, who also rely on glucocorticoids for day-to-day living.

As such, it is vitally important to recognize that "Injectable supplemental glucocorticoid therapy in this setting can reverse the risk of potentially fatal adrenal failure and should be considered in every case," Stewart and colleagues emphasize in a newly published editorial in JCEM.

They note this advice must be considered alongside World Health Organization (WHO) guidance against prescribing therapeutic glucocorticoids to treat complications of COVID-19, based on prior experience in patients with acute respiratory distress syndrome, as well as those affected by severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

The key difference here is not to use pharmacologic doses of glucocorticoids as treatment for COVID-19 (where they have no effect), but rather to prevent death from adrenal failure by using "stress" doses of replacement glucocorticoid, Stewart explained to Medscape Medical News.

"The intent here is to ensure that no patient with a history of prior exposure to chronic glucocorticoid therapy (> 3 months) by whatever route should die without consideration for parenteral glucocorticoid therapy," the editorialists write.

He advises using physiological stress doses of hydrocortisone (50-100 mg intravenously tid).

Specific Advice for Adrenal Insufficiency: Follow Sick Day Rules

A separate statement by the American Association of Clinical Endocrinologists (AACE) also emphasizes that it is particularly important for patients with adrenal insufficiency to follow advice from the Centers for Disease Control and Prevention (CDC) or similar guidance on preventing COVID-19 infection, including social distancing and frequent hand washing.

Such patients should continue to take medications as prescribed and ensure they have appropriate supplies of oral and injectable steroids, ideally for 90 days, AACE advises.

And if there is a shortage of hydrocortisone, the statement advises patients ask a pharmacist or physician about replacement hydrocortisone with different doses that might be available.

Stewart agrees that patients with adrenal insufficiency need to be hypervigilant, but says that "if they do become ill, for the most part they are well counseled to respond appropriately to intercurrent infections."

Nevertheless, it is "invaluable to reiterate 'sick day rules'" for suspected COVID-19 infection.

"Any patient who develops a dry continuous cough and fever should immediately double their daily oral glucocorticoid dose and continue on this regimen until the fever has subsided."

If a patient still deteriorates on this regimen, develops diarrhea or vomiting, or is unable to take oral glucocorticoids for other reasons, they should contact their physicians or seek urgent medical care to receive parenteral treatment with a glucocorticoid.

References

2020 WebMD, LLC. All Rights Reserved.

More here:
Corticosteroids With COVID-19 in Asthma, Allergies, and Arthritis Patients - MedicineNet

Physician-scientists at Beth Israel Deaconess Medical Center (BIDMC), part of Beth Israel Lahey Health, are now enrolling patients in a clinical trial to evaluate a potential treatment of patients with COVID-19. Part of a multi-site investigation, the trial is evaluating the safety and efficacy of sarilumab, a biologic medication already approved for adults with moderately to severely active rheumatoid arthritis, for the treatment of COVID-19. Pulmonary specialist Robert Hallowell, MD, Medical Director of BIDMCs Pulmonary Clinic, is leading the Phase 2/3 trial, which was initiated by Regeneron and Sanofi March 16, 2020.

While the symptoms of COVID-19 are mild for many, roughly 15 percent are at risk of developing an aberrantly robust immune reaction, which in its most severe form can lead to respiratory failure and, potentially, death, said Hallowell. The ability to stop this reaction in its tracks would be a major step forward in the management of COVID-19, both for infected individuals and for hospitals on the front line of this pandemic.

An inflammatory-inhibitor, sarilumab was developed by Regeneron and Sanofi to block interleukin-6 (IL-6), an immune factor called a cytokine that is involved in the overactive inflammatory response that is a common feature of autoimmune disorders like rheumatoid arthritis. The body releases cytokines inlacing IL-6 as part of its normal immune response to injured or infected tissues. In the average person, cytokines are responsible for symptoms such as redness and swelling around a wound or infected site. In patients with autoimmune disorders, cytokines can drive the immune response that attacks otherwise healthy tissues, such as cartilage in patients with rheumatoid arthritis or the cells of the pancreas in some people with type 1 diabetes.

Similarly, an overactive inflammatory response is thought to be the cause of the lung damage and respiratory distress in a significant percentage of patients with severe COVID-19. As the immune system releases cytokines to kill the virus, infected cells in the lungs become collateral damage. In turn, this injury to the lung tissues triggers additional inflammation, and the so-called cytokine storm begins to spiral out of control. The result can be lasting lung damage and scarring, organ failure or death.

Designed to halt this cytokine surge, sarilumab has the potential to improve outcomes for patients with severe cases of COVID-19, as well as reduce the expected demand for ventilators at present the only course of treatment for acute respiratory failure for patients with severe cases of COVID-19.

We have enrolled eight patients at BIDMC since opening the trial and plan to enroll several patients a day until the trial ends as a way of offering this potential treatment to the community, said Hallowell, who is also an Assistant Professor of Medicine, Harvard Medical School.

Hallowells clinical trial is one of several efforts fostered by the BILH COVID-19 Innovation Hub, an effort led by Gyongyi Szabo, MD, PhD, Chief Academic Officer at BIDMC and Beth Israel Lahey Health to meet the emerging challenges of the COVID-19 pandemic. Other projects include research into a potential vaccine for the prevention of COVID-19, clinical trials to evaluate the antiviral medication remdesivir, and efforts to source and produce critical medical supplies and equipment.

As of now, patients with COVID-19 receive the gold standard treatment of supportive care across our hospital system, but we continue to pursue new ways to care for them, said Szabo. If this drug can prevent patients from becoming gravely ill with COVID-19 or reduce the time it takes patients to recover, it could save lives.

Hallowell's BIDMC collaborators include C. Sabrina Tan, MD, Ari L. Moskowitz, MD, Debby Ngo, MD, Noah Schoenberg, MD, Kathryn Stephenson, MD, MPH, and Gyongyi Szabo, MD, PhD.

Read more here:
Statement: BIDMC enrolling patients in clinical trials evaluating existing drug as treatment for severe COVID-19 - Wicked Local

Elderly people may have to be kept isolated until the end of the year to protect them from the coronavirus, EU chief Ursula von der Leyen said in comments published Sunday.

"Without a vaccine, we have to limit as much as possible contact with the elderly," she told the Germany daily Bild.

"I know it's difficult and that isolation is a burden, but it is a question of life or death, we have to remain disciplined and patient," she added.

"Children and young people will enjoy more freedom of movement earlier than elderly people and those with pre-existing medical conditions," she said.

ALSO READ: Over 22,000 healthcare workers infected by Covid-19 globally: WHO

She said she hoped that a European laboratory will develop a vaccine towards the end of the year.

To ensure that people can be quickly vaccinated, authorities are already in talks with producers on gearing up for world production, she added.

ALSO READ: Covid-19: Effective quarantine could cut healthcare load by 90%, says study

Social isolation for elderly can pose health risks

Social isolation or self isolation among older adults can pose as a serious health concern because of their heightened risk of physical and mental conditions: high blood pressure, heart disease, weak immune system, depression and even death.

Apart from affecting health and well-being, social isolation can also lead to osteoarthritis (arthritis) in older adults, suggests a recent study.

Some 30 per cent of adults aged 65 and older have arthritis to some degree, especially in their leg joints.

Despite that, until now there has been little research on the relationship between arthritis and social isolation.

Those who weren't socially isolated tended to be younger had higher incomes and more education. They were also more likely to be physically active, had less physical pain, had faster walking times and were in better all-around health.

Because social isolation can worsen your health, the researchers suggested that older adults with arthritis perhaps could benefit from physical activity and participating in social activities.

See the original post:
Social isolation for elderly may last until the end of the year: EU chief - Business Standard

This innovative data linking will enable us to better understand how common MSK conditions are, how they progress, what treatments are best and who needs which services and when.

It is one of two projects awarded funding in partnership with the charity Versus Arthritis, who have contributed 250,000 towards the grants.

It will link existing, and new, data in novel ways, to address key research questions and inform policy and practice:

Tim Gardam, Chief Executive of the Nuffield Foundation said: The Nuffield Foundation is committed to improving peoples lives through better understanding of the issues affecting their life chances. Together these new projects will improve our understanding of the impact of MSK conditions on both individuals and wider society. We are delighted to be partnering with Versus Arthritis to help improve the health and well-being of people living with MSK conditions by influencing future practice, policy and research.

Amanda Neylon Director of Insight Data and Technology at Versus Arthritis said: This is exceptional research that will greatly improve our understanding of the effects of arthritis and improve the way people are treated. Meaningful data are key to providing high value musculoskeletal services as its essential for understanding the health needs of local populations, the activity performed by services and the outcomes they deliver.

Our partnership with the Nuffield Foundation is an excellent example of how working with others can maximise the impact of research funding and allow us to achieve more than we could do on our own.

Read the rest here:
1.5 million for research to improve the lives of people living with musculoskeletal conditions - The University of Manchester

- Advertisement -

However, as modern medicine extends the human lifespan, our species have learned pain in the form of osteoarthritis that can accompany the locomotion of this biomechanical masterpiece.

In a new study of the genetic features that help make this sophisticated joint possible, an international team of researchers found that the regulatory switches involved in the development of the knee also play a role in osteoarthritis, a partially heritable disease that afflicts at least 250 million people worldwide. The findings are published in the journalCell.

Terence D. Capellini, Richard B. Wolf Associate Professor in the Department of Human Evolutionary Biology and the papers corresponding author, explained it in terms of the burden our knees literally endure:

From an evolutionary standpoint, the primate knee went from something that accommodated the forces of walking on four legs to placing all the weight on two legs, he said. Going from a quadruped to a biped changes the force distribution. All our weight is being transmitted through our hips and our knees down to our ankles. The cells in the joint and the shape of the joint had to change to accommodate those new forces.

With such a specific task and limited by its origins in the older primate knee the optimized bipedal knee developed what is known as a constrained morphology, that is, it did not allow much variation. As you can imagine, when youre designing a part for an airplane, you dont want to stray too much, Capellini said.

To understand how this complex mechanism came to be, researchers looked for evidence of accelerated natural selection: the series of mutations that aided us in walking upright.

We wanted to know whether or not we could see signs of ancient evolution ancient selection in the regions of the genome that specifically sculpt the knee, said Capellini. To do this, they searched for traces of specific regulatory switches, pieces of DNA responsible for turning on and off the genetic material that make the knee a human knee.

What they found reflects what Capellini suggests is indicative of positive selection evidence that this new knee gave the fledgling bipeds an evolutionary advantage. The highest functioning knees would have been selected, reducing variation in knee shape over time by decreasing the genetic variation in the switches that control the joints formation. What variation persisted likely didnt substantially matter at that time.

Later, as human populations expand and drift, you start getting these genetic variants that slightly modify how the knee is shaped or how the knee is maintained, explained Daniel Richard, a Ph.D. candidate in human evolutionary biology and lead author on the paper. Those slight deviations, acting on this constrained knee, lead to risk for developing osteoarthritis.

Those traits did not affect the success of the bipedal knee because natural selection promotes traits that allow individuals to reach sexual maturity and successfully breed. In essence, because this new knee gave young adults an edge on passing on their genetic material, it continued despite these variants. Our eventual old age had little role in its selection.

We think that these slight modifications dont so much impact early life, said Richard. But when you keep on walking up until youre 50 or 60, over that longer time span a super small change in your knee compounds over decades. Eventually it contributes to osteoarthritis disease in the elderly.

As a proof of principle, Capellini and colleagues performed two additional experiments. By studying the knee switches in patients with osteoarthritis compared to the general population, they found that osteoarthritis patients have on average more genetic variants in switches than those who dont have the disease. They also focused on a gene called GDF5 (Growth Differentiation Factor Five) that contributes to osteoarthritis risk in Europeans and Asians. Using CRISPR editing in mice and human cells, they pinpointed a genetic variant, present in billions of people, that effects the function of a key knee switch, thus changing knee shape and increasing osteoarthritis risk.

The stiffness and soreness humans feel today, therefore, may simply have piggybacked on an evolutionary advantage: the osteoarthritis came along with the knee. However, this painful feature may pay off in the study of human evolution, the researchers stress.

The idea of tying new features with almost new diseases is a good mental framework to think of while studying these diseases of aging, said Richard. You cant really have your cake and eat it too.

HARVARD UNIVERSITY

Header Image A visual riff on the classic illustration, March of Progress, highlighting the evolution of knee osteoarthritis. Credit : Tasha McAbee, Department of Orthopedics at Boston Childrens Hospital

- Advertisement -

See the original post:
The evolution of arthritic knees - HeritageDaily

Transcript

When U.S. President Donald Trump urged medical professionals to take a malaria medication to protect themselves from COVID-19, he asked: "What do you have to lose?"

Eden Robinson knows the answer to that question all too well.

The Canadian author took hydroxychloroquine for eight months to manage pain from her rheumatoid arthritis, and experienced some of the more severe side effects associated with the drug, including vision loss. Shewrote about her experience for the Globe and Mail.

Hydroxychloroquine is used to treat malaria, as well as inflammatory disorders such as rheumatoid arthritis and lupus. There is no evidence it can protect people from contracting COVID-19, the disease caused by the coronavirus.

The jury is still out on whether it can be an effective treatment for COVID-19.To test that idea further, Canada'sMcGill University isconducting a randomized trial that is expected to include as many as 1,500 people. Another 1,500 people are enrolled in a similar study in the United States.

Public health officials including Canada's chief public health officer Dr. Theresa Tam have repeatedly warned that hydroxychloroquine can be extremely dangerous, with potential side effects that include irregular heartbeat, low blood sugar, mood changes and psychosis.

Robinson spoke to As It Happens host Carol Off about her experience with the drug. Here is part of their conversation.

When you hear Donald Trump saying "What do you have to lose?" and say look at the benefits ofhydroxychloroquine, what do you say to that? What do you want to tell Donald Trump?

You knowwhen you have the commercial for drugs and at first they give you all the wonderful things they can do, and then they have that very soothing voice that comes afterwards and tells you all the possible side effects? I think we're missing that soothing voice.

Speaking strictly from my own experience, after month five, I started seeing floaters and the floaters just kept increasing. And then I started getting eye pain. And if you've ever had a migraine if you can imagine your migrainesin your eye, that was my experience withhydroxychloroquine.

If you take this medication without being medically supervised, you know, you could win the worst lottery ever if you are one of the rare people that have retinal detachment as your side effect.

If you are taking it just because you, like, bought it off the internet, you thought Donald Trump made a point, if you start seeing halos around everything that you're looking at, you are in danger of losing your eyesight.

This is, of course, not reversible. This is a permanent damage you're talking about.

This is permanent damage.

When you are given Plaquenil [a brand name forhydroxychloroquine] from a doctor or a rheumatologist, there's a protocol that you have to follow, and you have to get a baseline eye exam from an ophthalmologist. And you go back every six months so that they can monitor if there's any buildup in your eye.

Towards the end of the eight months Iwas on Plaquenil,I was seeing so many floaters, it was like a snow globe. So it made it really hard to drive, really hard to read, really hard to do anything that required near sight.

We know that because of what Donald Trump's had to say, it has given a tremendous bump to sales of hydroxychloroquine.... So what do you say to those people who are now not just thinking they can treat COVID-19, but lots of people trying to get ahold of the drug because they believe what the president said that it can prevent them from getting it?

If you're hoarding this drug to prevent or treat COVID-19, you know, there's no real studies yet to say that it can do this and you are risking your own health to take this.

And at the same time, you are taking drugs away from people who actually need it. You're taking drugs away from a very vulnerable population.

People with rheumatoid arthritis and people with lupus who do well on this drug need to take it regularly. If you don't take your arthritis medication regularly, you risk capping an arthritic flare.When you have a flare, your symptoms come back and sometimes they come roaring back.

If you are taking this for lupus, that's even more critical. Lupus is an autoimmune disorder that attacks your body the same way that arthritis does. But if itstarts attacking one of your organs because you can't take your medication regularly, then that puts you at risk for organ failure.

And if you have one of your organs failing during a pandemic when your immune system is compromised, you know, the results are pretty grim.

For yourself, why did you feel it was necessary to put this message out?

When Donald Trump was talking I just wanted to be thelittle voice that comes after on the commercial that tells you these are the possible side effects just to raise people's awareness that, you know, these aren't Tic Tacs. These have potentially life-altering side effects.

Written by Sheena Goodyear with files from AminaZafar and CBC News.Interview produced by Chloe Shantz-Hilkes. Q&A has been edited for length and clarity.

Excerpt from:
'These aren't Tic Tacs': Author Eden Robinson on her experience with hydroxychloroquine - CBC.ca

President Trump has been a cheerleader for the drug hydroxychloroquine, pointing in a tweet and in person to a French study as evidence that one particular drug combination might be one of the biggest game changers in the history of medicine.

But now the medical society that published the French research has issued a statement saying theyre reviewing the study again and a correction to the scientific record may be considered.

Dr. Kevin Tracey, president and CEO of the Feinstein Institutes for Medical Research in New York City, gave an even more pointed assessment of the French research.

The study was a complete failure, he said.

It was pathetic, added Art Caplan, head of the division of medical ethics at the New York University School of Medicine.

The small French study of 20 people found that taking hydroxychloroquine was associated with the viral load reduction/disappearance in COVID-19 patients, noting that the effect was reinforced with azithromycin, an antibiotic better known as a Z-pack.

Tracey and Caplan pointed out that several patients who took the drug, and ended up faring poorly, dropped out of the trial, and their outcomes were not factored into the studys final conclusions.

The International Society of Antimicrobial Chemotherapy published the study online in its journal, the International Journal of Antimicrobial Agents, on March 20.

The society and the publisher of the journal, Elsevier, issued a joint statement that concerns have been raised regarding the content, the ethical approval of the trial and the process that this paper underwent to be published within International Journal of Antimicrobial Agents.

According to the statement, the study authors had been contacted to address concerns, and that additional independent peer review is ongoing to ascertain whether concerns about the research content of the paper have merit.

One of the studys co-authors, Jean-Marc Rolain, is also editor-in-chief of the journal.

The statement noted that Rolain was not involved in the peer review of the manuscript.

The statement from the society and Elsevier is dated April 3, but a previous statement with the same date was on the same webpage and has since been removed.

That statement by Andreas Voss, president of the society, said the study does not meet the Societys expected standard and that although ISAC recognises it is important to help the scientific community by publishing new data fast, this cannot be at the cost of reducing scientific scrutiny and best practices.

Voss, Rolain and Didier Raoult, a lead study author, did not immediately respond to CNN emails seeking comment.

Rarely does one unproven drug make such headlines, but hydroxychloroquine did due to Elon Musk, conservative media and Trump.

A recent article in Vanity Fair laid out the sequence of events.

On March 16, Musk, the Tesla CEO, tweeted that it maybe worth considering chloroquine for C19. Hydroxychloroquine is a derivative of chloroquine, and C19 is Covid-19, the medical term for the disease caused by the coronavirus.

Two days later, Breitbart and The Blaze wrote glowing articles about chloroquine.

The day after that, Trump said chloroquine was possibly a game changer at a White House briefing.

Two days later, on March 21, Trump referred to the French study in a tweet, saying that the combination of hydroxychloroquine and azithromycin have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains Thank You!

Trumps enthusiasm for hydroxychloroquine hasnt waned with time, even though its one of many drugs being studied to prevent or treat coronavirus, and none of them have been proven to be safe or effective.

We have some very good results and some very good tests. Youve seen the same test that I have, he said at an April 5 briefing. In France, they had a very good test.

In its statement, the society that published the paper mentioned concerns about the lack of better explanations of the inclusion criteria in the study, which took place at the Mditerranne Infection University Hospital Institute in Marseille, France.

The study started out with 26 patients taking the hydroxychloroquine, but six were lost in follow up during the survey because of early cessation of treatment, according to the study.

Three left because they ended up in the intensive care unit, another patient died, and a fifth stopped treatment due to nausea. It turned out the sixth patient didnt actually have coronavirus.

Leaving out the five patients who took the drug and didnt fare well is cherry picking, said Caplan, the bioethicist.

Thats not science, he said. Youve got your thumb on the scale.

The remaining 20 patients took hydroxychloroquine, some with the antibiotic azithromycin and some without, and their outcomes were compared with patients who did not take either drug.

The study authors wrote that 100% of patients who took the drug combination were virologically cured compared to 57.1% of the patients who took hydroxychloroquine alone and 12.5% of the control group. The authors did not fully explain what they meant by virologically cured.

Caplan added that even without the cherry picking issue, a study with such a small number of patients is basically meaningless.

Its just a jumbled mess, he said.

Several centers are doing clinical trials on hydroxychloroquine to prevent or treat coronavirus, including Harvard, Columbia, New York University and Henry Ford Health System in Detroit.

Tracey, the researcher at the Feinstein Institutes in New York City, is also conducting a study on the drug. He said despite the French study being seriously flawed, its still worth looking at hydroxychloroquine to see if its safe and effective for a subset of coronavirus patients.

First, he noted that hydroxychloroquine has anti-inflammatory properties. The US Food and Drug Administration has approved its use against lupus and rheumatoid arthritis, both diseases that involve inflammation.

Hydroxychloroquine might help coronavirus patients who experience whats called a cytokine storm, a potentially deadly inflammatory process.

And small studies other than the seriously flawed French one have shown that the drug might work, he added.

Theres a lot of small studies in humans and in the lab that frame an appropriate question thats never been answered in a clinical trial, he said. Its important to know if it works and if its safe in some people with coronavirus.

Originally posted here:
Publisher of hydroxychloroquine study touted by Trump says the research didn't meet its standards - KVIA El Paso

Orlando, Fla., April 07, 2020 (GLOBE NEWSWIRE) -- Mission Biotech, an educational, immersive 3D game featuring many hours of gameplay and challenges, is being offered free to educators as well as students interested in learning how scientists search and test for clues to identify a virus during a pandemic outbreak.

The game presents an immersive storyline that teaches middle-school students and above the laboratory protocols and the real-world concepts, procedures, and tools of the biotechnology field. This free download is being announced in response to the COVID-19 outbreak to support teachers and students as they adapt to new ways of learning during this challenging time.

Mission Biotech is a great way to encourage careers in biotechnology, said Randy Brown, Applied Research Associates, Inc. (ARA) vice president and division manager of Virtual Heroes, which developed the game. This game offers students a way to play, learn, and become a real hero of tomorrow.

In the game, users play as part of a virtual team trying to stop the spread of dangerous pathogens, and the clock is ticking. The player is a new member of the National Laboratory for Biotechnology and Bioinformatics. On this, their first mission, players need to learn laboratory protocol while also understanding the basic scientific concepts behind biotechnology processes.

Gameplay includes discovering and using high-tech, fully-functional laboratory equipment, and features more than 50 different inventory items and a wide range of clues to find and use. Players can collect up to 20 accomplishment badges and unlock mini-games; these games also reinforce the scientific concepts behind DNA extraction and Polymerase Chain Reaction (PCR) processes. These processes are being used in real life today to test for pathogens such as the novel coronavirus. Reference materials are also available for educators and learners on the download site.

With schools closing across the nation, we want to do our part to leverage any educational opportunities we can, Brown said. This software is an opportunity for students everywhere to engage in immersive biotech learning content while gaining a real-world understanding of the challenges facing scientists today.

Mission Biotech was funded by a grant from the National Science Foundation to the University of Florida, and developed on the Epic Games Unreal Engine by the Virtual Heroes Division of Applied Research Associates, Inc. This educational outreach is being coordinated between ARA, the Serious Play Conference, and the National Center for Simulation, all in Orlando, Florida.

Visit https://youtu.be/exMqEG-qOf8 for a game overview and then go to http://www.virtualheroes.biz/MissionBiotech to download Mission Biotech and start learning today.

Here is the original post:
Free First-Person Adventure Game Allows Students to Learn Biotechnology Processes As They Hunt for the Virus during a Pandemic - GlobeNewswire

The latest report published by Verified Market Research contains an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals Market. The research report assesses the constantly changing market dynamics, which should affect the overall market development. Analysts have examined historical market success and compared it with current market trends to determine the course. For a detailed discussion of the Nanoparticles in Biotechnology and Pharmaceuticals market, analysts have segmented the market by application, product and end user. The research report was compiled using primary and secondary research methods to provide readers with an accurate and precise understanding of current developments in the Nanoparticles in Biotechnology and Pharmaceuticals market.

The Nanoparticles in Biotechnology and Pharmaceuticals Market Report includes the Competitive Landscape section, which provides a comprehensive and in-depth analysis of current market trends, evolving technologies and developments that benefit competitive businesses in the market. The report provides an overview of sales, demand and supply of data, futuristic costs and an analysis of growth over the forecast year.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=GEN&utm_medium=005

The Nanoparticles in Biotechnology and Pharmaceuticals Sales Market Report mainly contains the following Manufacturers:

Market size and limitation Nanoparticles in Biotechnology and Pharmaceuticals:

In recent years, the number of consumers has increased and innovative technologies in the industry are driving the broad growth of the market. The increasing preference of consumers affects the industry as an opportunity or a threat. Preferences and priorities act as idols as drivers of the growth of the market system. Industry experts always agree with the shortcomings. The biggest threat to the industry is changing technology every day

Why Buy This Report?

The report provides a comprehensive analysis of the Nanoparticles in Biotechnology and Pharmaceuticals market with detailed studies on various topics that will help players develop powerful growth strategies and consolidate a strong position in the industry. It offers a complete map of the behavior of market participants and the supplier landscape. Readers also receive information about key sustainability strategies that large companies use in the Nanoparticles in Biotechnology and Pharmaceuticals market. In addition, analysts have carefully evaluated the impact of these strategies on market growth and competition. Players could use the report to better prepare for future market challenges and strong competition in the Nanoparticles in Biotechnology and Pharmaceuticals market.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=GEN&utm_medium=005

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology 3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=GEN&utm_medium=005

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Follow this link:
Nanoparticles in Biotechnology and Pharmaceuticals Market Challenges, Key Vendors, Drivers, Growth Opportunities and Forecast to 2026 - Germany...

New Jersey, United States:The new report has been added by Market Research Intellect to provide a detailed overview of the Biotechnology Separation Systems Market. The study will help to better understand the Biotechnology Separation Systems industry competitors, the sales channel, Biotechnology Separation Systems growth potential, potentially disruptive trends, Biotechnology Separation Systems industry product innovations and the value / volume of size market (regional / national level, Biotechnology Separation Systems- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Biotechnology Separation Systems manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Biotechnology Separation Systems branch. Market participants can use the report to take a look at the future of the Biotechnology Separation Systems market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=207653&utm_source=GEN&utm_medium=888

The report examines the competitive environment scenario observed with key players in Biotechnology Separation Systems sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Biotechnology Separation Systems sales industry. According to studies, the Biotechnology Separation Systems sales market is very competitive and diverse due to global and local suppliers.

The Biotechnology Separation Systems Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Biotechnology Separation Systems market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Biotechnology Separation Systems market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Biotechnology Separation Systems for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207653&utm_source=GEN&utm_medium=888

Table of Content

1 Introduction of Biotechnology Separation Systems Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Biotechnology Separation Systems Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Biotechnology Separation Systems Market, By Deployment Model5.1 Overview

6 Biotechnology Separation Systems Market, By Solution6.1 Overview

7 Biotechnology Separation Systems Market, By Vertical7.1 Overview

8 Biotechnology Separation Systems Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Biotechnology Separation Systems Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/%ef%bb%bfbiotechnology-separation-systems-market-size-and-forecast/?utm_source=GEN&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Biotechnology Separation Systems Market Size, Biotechnology Separation Systems Market Growth, Biotechnology Separation Systems Market Forecast, Biotechnology Separation Systems Market Analysis, Biotechnology Separation Systems Market Trends, Biotechnology Separation Systems Market

See the rest here:
Biotechnology Separation Systems Market Growth Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Germany English News

Its great to see GeneReach Biotechnology (GTSM:4171) shareholders have their patience rewarded with a 56% share price pop in the last month. Zooming out, the annual gain of 150% knocks our socks off.

Assuming no other changes, a sharply higher share price makes a stock less attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that deep value investors might steer clear when expectations of a company are too high. One way to gauge market expectations of a stock is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

See our latest analysis for GeneReach Biotechnology

We can tell from its P/E ratio of 49.49 that there is some investor optimism about GeneReach Biotechnology. As you can see below, GeneReach Biotechnology has a higher P/E than the average company (19.0) in the medical equipment industry.

GeneReach Biotechnologys P/E tells us that market participants think the company will perform better than its industry peers, going forward. The market is optimistic about the future, but that doesnt guarantee future growth. So further research is always essential. I often monitor director buying and selling.

Probably the most important factor in determining what P/E a company trades on is the earnings growth. If earnings are growing quickly, then the E in the equation will increase faster than it would otherwise. And in that case, the P/E ratio itself will drop rather quickly. A lower P/E should indicate the stock is cheap relative to others and that may attract buyers.

In the last year, GeneReach Biotechnology grew EPS like Taylor Swift grew her fan base back in 2010; the 141% gain was both fast and well deserved.

Dont forget that the P/E ratio considers market capitalization. That means it doesnt take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Since GeneReach Biotechnology holds net cash of NT$177m, it can spend on growth, justifying a higher P/E ratio than otherwise.

GeneReach Biotechnologys P/E is 49.5 which is way above average (14.9) in its market. Its net cash position is the cherry on top of its superb EPS growth. So based on this analysis wed expect GeneReach Biotechnology to have a high P/E ratio. What is very clear is that the market has become significantly more optimistic about GeneReach Biotechnology over the last month, with the P/E ratio rising from 31.7 back then to 49.5 today. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is blood in the streets, then you may feel the opportunity has passed.

When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course you might be able to find a better stock than GeneReach Biotechnology. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
What Is GeneReach Biotechnologys (GTSM:4171) P/E Ratio After Its Share Price Rocketed? - Simply Wall St

Scott Robinson used to be an investment banker, so he has a pretty good idea why it's tough these days to raise money for his Cambridge biotechnology startup, MicroQuin even though the company believes its approach to fighting cancer could show promise against the coronavirus.

"At the moment, a lot of the funding has really been allocated to things that people are thinking are quick wins stuff like drug repurposing or vaccinations," he said.

For a handful of drugmakers taking on the coronavirus, fundraising is no problem right now. But for many other Massachusetts biotechs, the pandemic threatens to stop the flow of money.

If you're a company like MicroQuin, and you don't have a coronavirus vaccine candidate or a drug ready to test against COVID-19 good luck getting new financing.

And there's no telling when investors will feel comfortable spending again.

"We've seen many investors sort of push the pause button for the next quarter, as they assess the market," saidJonathan Norris, a managing director at Silicon Valley Bank. He spoke this week on a virtual panel organized by LabCentral, the Kendall Square workspace where Robinson's company and about 70 others are based.

"We just don't know how long this pandemic is going to last," Norris said. "The big financial questions that investors are talking about are, 'What's going to happen in the public markets? Will IPOs happen?'"

Initial public offerings of stock can be critical to biotechs. They often infuse cash into young firms that have raised venture capital but don't yet have any FDA-approved drugs to produce revenue.

The Nasdaq Biotechnology Index has recovered some losses, after falling more than 20% last month. But it's still a scary time, said Robert Urban, the former head of Johnson & Johnson's innovation division. J&J has secured a $1 billiondeal including federal grants to try to develop a vaccine, but most companies aren't in that position.

"We have some tough days ahead and maybe tough months ahead," Urban said of the biotech industry. "So, anyone who's running a business a life science business, in some ways, may be even more difficult because they require so much money needs to be taking some very careful care of the decisions that they make."

Urban and Norris were joined on the LabCentral panel by Matt McTygue, an attorney who represents venture capitalists. It's not that investors aren't doing any deals, McTygue said, but he offered a warning: "Financings that do happen during this time are going to be on more investor-favorable terms, more dilutive terms."

In other words, entrepreneurs who are desperate for funding may have to give up bigger-than-usual ownership stakes in their companies.

Read the rest here:
Biotech Firms May Be Key To Beating The Coronavirus, But They're Not Immune To Financial Worry - WBUR

The COVID-19 outbreak is gripping our planet like no other health crisis in recent history. Overt collaboration and policy action are required to meet this challenge and, as importantly, prepare for the future. Elevating and prioritizing the interconnectedness of living things through One Health strategies and modernizing Americas animal biotechnology regulatory approach are two policies Congress and the White House must confront. In fact, they are long overdue.

Sixty percent of human diseases begin in animals.Scientists are confident that the COVID outbreak originated in batsand then was spread through another animal and then to humans, like the 2002-03 SARS outbreak. As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

Aside from the dreadful health implications, the resulting economic costs of a pandemic are profound.The World Bank estimates that, between 1997 and 2009, the global costs from six zoonotic outbreaks exceeded $80 billion. While we wont know the total impact for some time, COVID-19 has already producedone of the sharpest economic downturns in U.S. history and is costing the U.S. treasury alone trillions of dollars.

Society was woefully unprepared for this pandemic. We must employ modern approaches to be ready for future outbreaks. One Health collaboration eliminates barriers that often exist between human health, animal health, and environmental health strategies to create smarter, multi-faceted and coordinated efforts.

BIO supports legislation such as the Advancing Emergency Preparedness Through One Health Act of 2019. This bill would direct the U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA) to coordinate with other agencies and state and local leaders to advance a national One Health framework to better prevent, prepare for, and respond to zoonotic disease outbreaks like COVID-19. Congress and the White House must factor One Health into their efforts to address future pandemics.

Animal health and wellness is a critical component of One Health strategy. To help the U.S. better prepare for the future, we need changes to the U.S. animal biotechnologyregulatory system.The U.S. governments current approach to regulating animal biotechnology as a new animal drug has all but destroyed investment and blocked market access for a host of beneficial products.

Biotechnology, for example, could armpigs with resistanceto African Swine Fever. Similarly,scientists have developed achickenthat is resistant to contracting and transmitting avian influenza.

Other innovations in animal biotechnology may be able prevent, prepare for, and respond to outbreaks of infectious diseases such as coronavirus, Ebola, MERS, Zika, among others, by providing prevention strategies andtreatments for humans.

Unfortunately, the United States regulatory system for animal biotechnology is not appropriately science- or risk-based, and as a result we are falling behind other countries, such as Brazil, where innovative start-ups are finding more support.

Indeed, despite decades of animal biotechnology research and advances, only one biotech food animal has been approved to date the AquaBounty salmon which languished in the U.S. regulatory system for more than two decades and still has not hit the market because ofpolitical interference.

The current crisis underscores the urgent need to break down roadblocks to progress.

BIO is calling on the White House to direct the U.S. Food and Drug Administration (FDA) and the USDA to clarify within 30 days a plan to overhaul the current regulatory approval process for animal biotechnology.

In alettersent to the President, BIO implores the need for a new approach that 1) more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment; 2) incentivizes research and investment in the technology; and 3) ensures safe and affordable products reach consumers as soon as possible.

A joint agreement between both agencies will help farmers, innovators, and consumers realize the benefits that modern technology can bring to the United States and the world. And just may well prevent the next potential animal to human disease outbreak.

Dana OBrien,Executive Vice President,Food & AgricultureBiotechnology Innovation Organization (BIO)

The rest is here:
Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement - Agri-Pulse

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the companys response, operationally and scientifically.

Dear Generex Shareholders,

The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain times the health and well-being of our Generex family, including our employees, shareholders, investors and partners is paramount. For the well-being of all of our stakeholders, we are committed to following the precautions of health advisors and adhering to suggestions, advice, and laws set up by local municipalities, cities, states, and the federal government to stop this pandemic that has disrupted the world. Generex Biotechnology remains dedicated to safeguarding your investment in GNBT as we continue working towards positive outcomes into the future through our strategic initiatives and development programs, including our previously announced efforts to develop a vaccine for the SARS-CoV-2 virus.

We want to take this time to update shareholders on the steps we are taking to efficiently manage the businesses of Generex and our subsidiaries through these challenging times. We are virtually fully operational with all our business management teams and their employees through video conference and are committed to following through with our short, mid and long-term goals and plans to add value for our shareholders.

As reported Generex has jumped into the vaccine race with its Ii-Key-COVID-19 Complete Vaccine, which is designed to activate both the cellular (CD4 and CD8 T cells) and humoral (antibody) immune responses. As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.

Generex has also partnered with EpiVax, a leader in computational vaccinology, that has developed algorithms to identify specific amino acid peptide sequences or epitopes that are predicted to activate the various cellular components of the immune system including CD4 T Cells, CD8 T Cells, and B Cells that produce antibodies. An additional advantage of their vaccinology algorithms is their ability to dehumanize peptide sequences to minimize autoimmune reactions. EpiVax has identified a series of epitopes of the SARS-CoV-2 viral proteins that may be used to produce a vaccine. Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.

To advance our vaccine development efforts, the team at Generex has been proactive in reaching out to a number of countries, and we have had productive conversations with several government officials, Ministries of Health, and other key influencers to describe our technology, our clinical strategy, potential manufacturing partners, and our rapid path to vaccination for their populations. Generex has also met and had discussions with U.S. government agencies to provide them with details of our Ii-Key peptide vaccine technology, and we are in discussions with the decision makers for federal funding and partnership. It has been a slow process, but we believe that vaccines are now getting more government attention as local, state, and federal officials recognize the severity of this pandemic and the likelihood that the virus will return next year.

Generex has identified a clinical research organization, regulatory consultants, and clinical research sites to conduct our trials, and we are working with our contract manufacturing partners for AE37 to produce our Ii-Key-SARS-CoV-2 peptide vaccine for human clinical trials and population vaccination initiatives. We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.

Story continues

Generex is highly confident in our rapid vaccine development program and in our plans to scale the manufacturing of Ii-Key- SARS-CoV-2 peptide vaccines to conduct not only the clinical trials required to meet the approval standards of global regulatory authorities, but to meet government expectations for mass population vaccination.

In conclusion, while the COVID-19 pandemic is surely a fast evolving situation with multiple layers of complexity, we believe market conditions should ultimately favor long-term minded, value oriented, and fundamental investors. Generex has many subsidiaries and many assets, from its FDA-cleared wound care product Excellegen, to our development products in inflammatory bowel diseases, diabetes, infectious disease, and cancer, to our pending operations in Arizona, with the ultimate vision of building a HMO with, in our opinion, unprecedented benefit packages through our own products, devices, and ancillary services. Based on all these efforts and assets, it is my belief that Generex has the staying power to thrive and bring value to our shareholders. Rest assured, Generex is well equipped to navigate the current environment as we remain focused on our core competencies and businesses while positioning our high-value assets for the future.

In the immediate days ahead, we will continue working to solidify the development path and government partnerships to complete our Ii-Key-SARS-CoV-2 Complete Vaccine program so that we can make a difference not only for Generex, our employees, and our shareholders, but for the world. Finally, we thank you all for your continued support as we navigate through this difficult period together, and please everyone, stay safe, be well and take care of your families and friends.

Sincerely,Joe MoscatoCEO

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

See the original post:
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic - Yahoo Finance

New DelhiAn anti-Covid consortium of experts with the assistance of Department of Biotechnology is working towards producing therapeutic antibodies against Covid-19.

In India, one such effort is being led by Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology.

Chaudharys group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.

These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.

This work is being undertaken as part of an Anti-Covid consortium under the leadership of Chaudhary and involving Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).

Covid 19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as diphtheria, tetanus, rabies and ebola.

Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2, a statement by Department of Biotechnology said. (IANS)

See original here:
Anti-Covid consortium in India working on therapeutic antibodies - India New England

Latest Report onAgriculture Biotechnology Market

The report titled Global Agriculture Biotechnology Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Agriculture Biotechnology market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Agriculture Biotechnology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Agriculture Biotechnology market is carefully analyzed and researched about by the market analysts.

Agriculture Biotechnology Market competition by top manufacturers/ Key player Profiled: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/692707

Global Agriculture Biotechnology Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Agriculture Biotechnology market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Agriculture Biotechnology Market Segment by Type covers: Biochips, Deoxy ribonucleic acid (DNS) sequencing, Genome editing tools, Ribonucleic acid interference (RNAI), Synthetic biology

Agriculture Biotechnology Market Segment by Application covers:Transgenic crops market, Synthetic biology-enabled products market

After reading the Agriculture Biotechnology market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Agriculture Biotechnology market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalAgriculture Biotechnology market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Agriculture Biotechnology market?What are the key factors driving the global Agriculture Biotechnology market size?Who are the key manufacturers in Agriculture Biotechnology market space?What are the market opportunities, market risk and market overview of the Agriculture Biotechnology market?What are sales, revenue, and price analysis of top manufacturers of Agriculture Biotechnology market?Who are the distributors, traders, and dealers of Agriculture Biotechnology market?What are the Agriculture Biotechnology market opportunities and threats faced by the vendors in the global Agriculture Biotechnology industries?What are sales, revenue, and price analysis by types and applications of Agriculture Biotechnology market?What are sales, revenue, and price analysis by regions of Agriculture Biotechnology industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/692707

Some of the Major Highlights of TOC covers:

Agriculture Biotechnology Regional Market Analysis

Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Revenue by RegionsAgriculture Biotechnology Consumption by RegionsAgriculture Biotechnology Segment Market Analysis (by Type)

Global Agriculture Biotechnology Production by TypeGlobal Agriculture Biotechnology Revenue by TypeAgriculture Biotechnology Price by TypeAgriculture Biotechnology Segment Market Analysis (by Application)

Global Agriculture Biotechnology Consumption by ApplicationGlobal Agriculture Biotechnology Consumption Market Share by Application (2014-2020)Agriculture Biotechnology Major Manufacturers Analysis

Agriculture Biotechnology Production Sites and Area ServedProduct Introduction, Application and SpecificationAgriculture Biotechnology Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/692707

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the rest here:
(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers...

Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The US$283m market-cap company announced a latest loss of -US$75.6m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on PBYIs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for PBYIs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Puma Biotechnology

PBYI is bordering on breakeven, according to the 8 Biotechs analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$11m in 2022. So, PBYI is predicted to breakeven approximately 2 years from now. What rate will PBYI have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 62%, which is extremely buoyant. If this rate turns out to be too aggressive, PBYI may become profitable much later than analysts predict.

NasdaqGS:PBYI Past and Future Earnings April 8th 2020

Underlying developments driving PBYIs growth isnt the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with PBYI is its debt-to-equity ratio of over 2x. Typically, debt shouldnt exceed 40% of your equity, which in PBYIs case, it has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are too many aspects of PBYI to cover in one brief article, but the key fundamentals for the company can all be found in one place PBYIs company page on Simply Wall St. Ive also put together a list of key aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Follow this link:
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? - Yahoo Finance

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Here is the original post:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

EIDD-2801, an oral broad-spectrum antiviral proceeding into Clinical Trials

ATLANTA and MIAMI, April 6, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application by Drug Innovation Ventures at Emory (DRIVE), LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP (Ridgeback), a closely held biotechnology company. This action by the FDA allows Ridgeback to initiate human clinical testing of EIDD-2801 in the United States.

"We are thankful to FDA Commissioner Dr. Steven Hahn and his team at the Anti-Viral Division for the unprecedented speed in reviewing our submission, the guidance and the highly collaborative process that ensures this promising drug can advance into the clinical development as fast as possible," said Wendy Holman, Chief Executive Officer of Ridgeback. "We also appreciate the guidance we have received from the Assistant Secretary of Preparedness and Response (ASPR), including discussions that occurred months before COVID-19 first emerged, to help Emory/DRIVE advance the development of EIDD-2801 as quickly as possible to address this global pandemic."

EIDD-2801 prevents the replication of SARS-CoV-2, the virus that causes COVID-19, and has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. In addition to coronaviruses, EIDD-2801 has broad spectrum activity against a number of diseases of public health concern, including influenza, chikungunya, Ebola, and equine encephalitis (VEE and EEE). The antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).

"FDA's prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible," says George Painter, Ph.D., director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. "We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting COVID-19."

Ridgeback and DRIVE have established a partnership to advance EIDD-2801 through clinical development and to optimize availability during the current COVID-19 pandemic. EIDD-2801 was exclusively licensed to Ridgeback in March 2020.

"We look forward to our continued work with the highly experienced drug development team at DRIVE and the dedicated medical, public health and governmental personnel who are on the frontlines of this pandemic in the United States and abroad," says Wendy Holman, CEO of Ridgeback Biotherapeutics. "The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback brings its unique perspective, honed by our success developing an Ebola therapeutic during the 2018-2020 outbreak in the DR Congo, to help advance EIDD-2801 for the treatment of diseases that are critical to pandemics and global health."

About EIDD-2801:

EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. The development of EIDD-2801 has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075.

About Ridgeback Biotherapeutics LP:

Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00059 and 75A50120C0009.

About DRIVE:

DRIVE is a non-profit LLC wholly owned by Emory University and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVE's mission is to discover and develop antiviral drugs for emerging infections, pandemic threats, and biodefense (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis). Because these diseases are major threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVE's executive team, led by George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza.

About Defense Threat Reduction Agency:

The Defense Threat Reduction Agency (DTRA) was formally established on October 1, 1998. DTRA enables the Department of Defense, the United States Government and International partners to counter and deter weapons of mass destruction and improvised threat networks. As a Combat Support Agency and a Defense Agency, DTRA's mission is to counter the threats posed by the full spectrum of weapons of mass destruction (WMD), including chemical, biological, radiological, nuclear, and high-yield explosives; counter the threats posed by the growing, evolving categories of improvised threats, including improvised explosive devices, car bombs and weaponized consumer drones, as well as the tactics, technologies and networks that put them on the battlefield; and ensure the U.S. military maintains a safe, secure, effective and credible nuclear weapons deterrent.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

SOURCE Ridgeback Biotherapeutics LP

See the rest here:
FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 - BioSpace

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported Timothy P. Walbert, Chairman, President and CEO of Horizon Therapeutics plc, will succeed Chad Mirkin, Ph.D. as Chairman of Exicures Board of Directors. Dr. Mirkin, who will remain on the Board, is stepping down as Chairman due to his responsibilities at Northwestern University, where he is Professor and Director of the International Institute for Nanotechnology.

Tim Walbert has served as the president and chief executive officer of Horizon Therapeutics since 2008 and has served as chairman of its board of directors since 2010. Prior to joining Horizon, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company acquired by Takeda America Holdings, Inc. in 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biotechnology company. Mr. Walbert was also divisional vice president and general manager of immunology, where he led the global development and launch of the multi-indication biologic HUMIRA at Abbott, now AbbVie. Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, PA. He serves as chairman of the board of Zyla Life Sciences, co-chairman of the board of MATTER and serves on the board of the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is a member of the Illinois Innovation Council, the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College.

Exicure is poised to change pharmaceutical development by opening up the field of digital medicine with its proprietary spherical nucleic acid (SNA) technology. Exicures existing programs and pipeline are promising, and the Company has many untapped therapeutic areas yet to be tackled. I look forward to working with the Exicure team to advance the Companys current clinical programs and take the Company into its next stage of development, while continuing to build its pipeline of new therapeutic candidates, said Mr. Walbert.

It has been a pleasure to serve as Chairman since we founded the company in 2011 and to help guide Exicure, said Dr. Mirkin. We have created a clinically-focused company with growing opportunities in neurology and an asset in immuno-oncology that is looking promising in clinical trials for several indications. The platform and team are strong and the potential opportunities are significant. As we continue to execute on our strategy and bring candidates through the clinic into commercialization, Tims experience and leadership in this area will be extremely valuable.

Under Chads leadership, we built a leading platform company focused on developing therapeutics based on our technology, initiated a clinical program (XCUR-FRN) in Friedreichs ataxia, advanced our immuno-oncology candidate AST-008 into Phase 2 clinical trials, entered into an exciting partnership with Allergan in hair loss disorders and finished 2019 with $110 million of cash on hand, said Dr. David Giljohann, Chief Executive Officer of Exicure. I am looking forward to Tims leadership as we continue to grow Exicure, concluded Dr. Giljohann.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNAbased therapeutic candidate, for the treatment of Friedreichs ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and also has an office in Cambridge, MA.

For more information, visit Exicures website at http://www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward looking including, but not limited to, statements about the companys business strategy and plans, including its leadership in the field of digital medicine and development of product candidates based on its proprietary SNA technology and the companys transition from the clinic to commercialization; the advancement of the companys pipeline and product candidates; the potential of the companys collaborations and R&D efforts; and anticipated market opportunities for the companys product candidates in neurology and in immuno-oncology. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on managements current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the COVID-19 pandemic may disrupt the companys business and/or the global healthcare system more severely than anticipated, which may have the effect of further delaying our ability to enroll and complete the companys ongoing Phase 1b/2 clinical trial, unexpected costs, charges or expenses that reduce cash runway; that the companys pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments and the ability of Exicure to protect its intellectual property rights. Furthermore, data from preclinical studies often fails to be indicative of outcomes in human trials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Exicure undertakes no duty to update this information, except as required by law.

Continue reading here:
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board - Business Wire